Castle Historical Cash Flow
| CSTL Stock | USD 32.26 0.39 1.22% |
Analysis of Castle Biosciences cash flow over time is an excellent tool to project Castle Biosciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 53.8 M or Begin Period Cash Flow of 152.7 M as it is a great indicator of Castle Biosciences ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Castle Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Castle Biosciences is a good buy for the upcoming year.
Castle |
About Castle Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Castle balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Castle's non-liquid assets can be easily converted into cash.
Castle Biosciences Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Castle Biosciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Castle Biosciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Castle Biosciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Castle Biosciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.At this time, Castle Biosciences' End Period Cash Flow is quite stable compared to the past year. Change To Netincome is expected to rise to about 18 M this year, although the value of Change To Inventory is projected to rise to (3.8 M).
Castle Biosciences cash flow statement Correlations
Click cells to compare fundamentals
Castle Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Castle Biosciences cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 10.4M | 67.2M | (781K) | (1.7M) | (5.1M) | (4.9M) | |
| Change To Inventory | (355K) | (980K) | 327K | (1.7M) | (4.0M) | (3.8M) | |
| Investments | (937K) | (4.7M) | (66.7M) | (166.5M) | (13.0M) | (13.6M) | |
| Change In Cash | 94.4M | 311.0M | (80.2M) | (206.7M) | (24.1M) | (22.9M) | |
| Net Borrowings | 20.9M | (27.4M) | (8K) | (122K) | (109.8K) | (104.3K) | |
| Stock Based Compensation | 1.2M | 8.3M | 21.7M | 36.3M | 51.2M | 53.8M | |
| Free Cash Flow | 6.1M | 5.1M | (22.5M) | (47.3M) | (13.8M) | (14.4M) | |
| Change In Working Capital | 44K | 9.1M | (4.1M) | (7K) | (6.6M) | (6.3M) | |
| Begin Period Cash Flow | 4.5M | 98.8M | 409.9M | 329.6M | 122.9M | 152.7M | |
| Total Cashflows From Investing Activities | (937K) | (4.7M) | (66.7M) | (166.5M) | (149.9M) | (142.4M) | |
| Other Cashflows From Financing Activities | 88.3M | 3.2M | 5.4M | 4.2M | (2.4M) | (2.3M) | |
| Depreciation | 358K | 472K | 3.4M | 10.5M | 12.3M | 12.9M | |
| Other Non Cash Items | 2.4M | 823K | 33.0M | (19.5M) | 635K | 603.3K | |
| Capital Expenditures | 937K | 4.8M | 3.5M | 5.6M | 13.6M | 14.3M | |
| Total Cash From Operating Activities | 7.0M | 9.9M | (19.0M) | (41.7M) | (135K) | (141.8K) | |
| Change To Account Receivables | (896K) | 1.7M | (4.6M) | (6.2M) | (14.9M) | (14.2M) | |
| Change To Operating Activities | 738K | 8.3M | 384K | 7.3M | 8.4M | 8.8M | |
| Net Income | 5.3M | (10.3M) | (31.3M) | (67.1M) | (57.5M) | (54.6M) | |
| Total Cash From Financing Activities | 88.3M | 305.9M | 5.4M | 1.5M | (2.3M) | (2.2M) | |
| End Period Cash Flow | 98.8M | 409.9M | 329.6M | 122.9M | 98.8M | 167.5M | |
| Change To Netincome | (589K) | 9.7M | 13.0M | 14.9M | 17.2M | 18.0M | |
| Change To Liabilities | 557K | 169K | (182K) | 582K | 523.8K | 324.8K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share (0.12) | Revenue Per Share 10.554 | Quarterly Revenue Growth 0.735 | Return On Assets (0.02) |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.